clinical trial · NCT06124807
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company·phase2·completed·n = 179
ObesityOverweight and ObesityMazdutidePlacebo
brief summary
The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.
started
Nov 17, 2023
primary completion
Jan 22, 2025
completion
Jul 9, 2025
last updated
Apr 21, 2026
official title
A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol